Research programme: thrombopoietin antibody mimetic - Alexion

Drug Profile

Research programme: thrombopoietin antibody mimetic - Alexion

Alternative Names: Fab59

Latest Information Update: 16 Feb 2010

Price : $50

At a glance

  • Originator Alexion Pharmaceuticals
  • Class
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombocytopenia

Most Recent Events

  • 01 Jun 2007 Preclinical trials in Thrombocytopenia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top